Here's how ridiculous this valuation is. ARTH has
Post# of 72436
![Avatar](/images/ProfileImages/424989898_3046_Avatar jpeg2.jpg)
ARTH has ONE possible product, a new (and way better) surgical glue.
ONE product. Not very far in clinical trials -- FDA asked them for more patients in their Phase 1.
IPIX? Well, I need not rehash about 3 drugs with multiple applications, and nothing but successful clinical trials.
But I do not think that ARTH is overvalued. It's just that IPIX is so grossly undervalued.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)